Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain imm...
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory pa...
JMP Securities analyst Roy Buchanan reiterates Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and maintains $32...
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in olde...
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerabi...
JMP Securities analyst Roy Buchanan maintains Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and raises the pri...
